MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...

Full description

Bibliographic Details
Main Authors: Max Hardy-Werbin, Raúl del Rey-Vergara, Miguel Alejandro Galindo-Campos, Laura Moliner, Edurne Arriola
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
MET
HGF
Online Access:https://www.mdpi.com/2072-6694/11/10/1404
id doaj-1455d62de4534aa9974b33d33e6be087
record_format Article
spelling doaj-1455d62de4534aa9974b33d33e6be0872020-11-25T01:32:44ZengMDPI AGCancers2072-66942019-09-011110140410.3390/cancers11101404cancers11101404MET Inhibitors in Small Cell Lung Cancer: From the Bench to the BedsideMax Hardy-Werbin0Raúl del Rey-Vergara1Miguel Alejandro Galindo-Campos2Laura Moliner3Edurne Arriola4Cancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainMedical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, SpainCancer Research Program, IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), 08003 Barcelona, SpainSmall cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response.https://www.mdpi.com/2072-6694/11/10/1404small cell lung cancerMETHGFimmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Max Hardy-Werbin
Raúl del Rey-Vergara
Miguel Alejandro Galindo-Campos
Laura Moliner
Edurne Arriola
spellingShingle Max Hardy-Werbin
Raúl del Rey-Vergara
Miguel Alejandro Galindo-Campos
Laura Moliner
Edurne Arriola
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Cancers
small cell lung cancer
MET
HGF
immunotherapy
author_facet Max Hardy-Werbin
Raúl del Rey-Vergara
Miguel Alejandro Galindo-Campos
Laura Moliner
Edurne Arriola
author_sort Max Hardy-Werbin
title MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
title_short MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
title_full MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
title_fullStr MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
title_full_unstemmed MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
title_sort met inhibitors in small cell lung cancer: from the bench to the bedside
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-09-01
description Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Within the potentially interesting targets, the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition (MET) pathway activation is associated with worse survival and chemoresistance in SCLC. Preclinical data suggest that the inhibition of the MET pathway can revert chemoresistance and prevent tumor growth. Recently, immunotherapy has shown modest but relevant activity in SCLC. Interestingly, MET modulation seems to be involved in increasing the efficacy of standard checkpoint inhibitors. Here, we review the preclinical and clinical data of MET inhibition in SCLC, and the role of this pathway in the immune response.
topic small cell lung cancer
MET
HGF
immunotherapy
url https://www.mdpi.com/2072-6694/11/10/1404
work_keys_str_mv AT maxhardywerbin metinhibitorsinsmallcelllungcancerfromthebenchtothebedside
AT rauldelreyvergara metinhibitorsinsmallcelllungcancerfromthebenchtothebedside
AT miguelalejandrogalindocampos metinhibitorsinsmallcelllungcancerfromthebenchtothebedside
AT lauramoliner metinhibitorsinsmallcelllungcancerfromthebenchtothebedside
AT edurnearriola metinhibitorsinsmallcelllungcancerfromthebenchtothebedside
_version_ 1725080049059627008